EBioMedicine March 2019 PMID 30737084

Senolytics and senostatics as adjuvant tumour therapy.

Susan Short, Edward Fielder, Satomi Miwa, Thomas von Zglinicki

Full text PDF Download social card

Mentions

Peak: 2 in Feb 2019

across 4 sources since Feb 2019

Extended reach

3,976

potential audience

Total likes

Video views

Mentions per month

Feb 2019 – Mar 2021

Where it's discussed

News6 articles
X / Twitter4 posts
Blogs2 articles
YouTube1 videos

AI synopsis

What people are saying

The posts mainly serve as acknowledgments of the publication, such as sharing links and referencing related research, with phrases like 'Read our latest review' and hashtags indicating a focus on awareness rather than in-depth discussion. The tone is informative and concise, reflecting moderate interest and engagement with the content's implications.

AgreementModerate agreement

Most discussions recognize the potential benefits of senolytics and senostatics in cancer therapy, indicating general agreement with the publication’s premise.

InterestModerate interest

Posts show moderate interest by mentioning the publication and related news, but lack detailed analysis or debate, suggesting they are somewhat interested but not deeply engaged.

EngagementModerate engagement

The mention of reviews, summaries, and the inclusion of hashtags points to a basic level of engagement, but there's limited discussion or critical analysis.

ImpactModerate impact

The posts highlight the relevance of the research to cancer treatment and aging, implying recognition of its significance, but they do not reflect widespread influence or transformative effects yet.

Abstract in brief

Tumor cell senescence can help slow cancer growth, but it is often incomplete, and some cancer cells recover and become more aggressive, potentially worsening outcomes.
Senescence in surrounding cells and spreading effects can elevate the overall burden of senescent cells, which may lead to aging-related issues like frailty and increased mortality in cancer survivors.
New drugs called senolytics and senostatics are being explored to kill or suppress these senescent cells, which could improve cancer treatment outcomes and reduce aging-related health problems in survivors.]

Read the full abstract

All mentions

The Role of Senescent Cells and Inflammation in Age-Related Cancer Risk

Aging increases malignant tumor risk linked to chronic inflammation and senescent cells. Short-term increases in senescence can influence cancer progression, highlighting the potential of senolytics and senostatics as…

Galactic Future and Eternal Life for Humans · Mar 26, 2021 93 views

sophia de rooij

@sophiaderooij · X

Senolytics and senostatics as adjuvant tumour therapy. - PubMed - NCBI #oncology #Ageing #senolytics https://t.co/UyjjTtk6RQ

Oct 25, 2019 · 1,947 followers View post →

Europe PMC articles

@EuropePMC · X

New from #BBSRC https://t.co/vfFGy4WDj1 Senolytics and senostatics as adjuvant tumour therapy

Apr 12, 2019 · 1,553 followers View post →

Duc Le

@duchongle · X

RT @EBioMedicine: Read our latest review article: #Senolytics and #senostatics as adjuvant #tumour therapy https://t.co/btOWiSzz8X https://…

Feb 8, 2019 · 2 shares · 264 followers View post →

Daniel Stuckey

@DanielStuckey1 · X